MedAdvisor Limited (AU:AHE)
ASX:AHE
Want to see AU:AHE full AI Analyst Report?
AHE Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.09
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.73M
Market Cap
AU$10.84M
Enterprise ValueAU$17.93M
Total Cash (Recent Filing)AU$10.30M
Total Debt (Recent Filing)AU$17.40M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding637,676,800
10 Day Avg. Volume474,818
30 Day Avg. Volume1,728,714
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)11.59
Price to Sales (P/S)0.19
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$110.67M
Bulls Say, Bears Say
Bulls Say
Platform Business With Consumer AppMedAdvisor’s integrated pharmacy platform and consumer medication app create a stickier, recurring engagement model across prescription workflows and adherence. This product-led network ties pharmacies and patients, supporting recurring service revenue and long-term customer retention if execution and adoption persist.
Improving Free Cash Flow TrendAn 18.49% rise in free cash flow indicates improving cash generation versus prior periods. If sustained, improved FCF supports reinvestment, product development or reduces external financing needs, improving resilience despite operating cash flow headwinds in the nearer term.
Positive Return On EquityA positive ROE signals the business can generate returns from shareholder capital even amid broader distress. This operational efficiency suggests core unit economics can be favorable and may enable recovery or profitable scale-up if revenue loss trends reverse and margins improve.
Bears Say
Steep Revenue DeclineA ~39% annual revenue contraction materially weakens scale economics and reduces the ability to spread fixed costs. Sustained revenue declines undermine long-term margin recovery, hinder platform monetization, and raise the bar for returning to profitable growth absent renewed client adoption or new revenue streams.
Very Weak Profitability MarginsDeep negative margins indicate the company is burning cash on core operations, reflecting structural cost or pricing issues. Persistent losses limit capacity to self-fund growth or product investment and increase dependency on external capital, threatening sustainability over the medium term.
Precarious Balance Sheet And Solvency RiskNegative shareholders' equity and a debt-to-equity of -10.75 signal solvency and capitalization issues. This structural weakness constrains financing options, raises refinancing or covenant risks, and can force dilutive capital raises or asset restructuring, impairing long-term strategic flexibility.
MedAdvisor Limited News
AHE FAQ
What was MedAdvisor Limited’s price range in the past 12 months?
MedAdvisor Limited lowest share price was AU$0.02 and its highest was AU$0.09 in the past 12 months.
What is MedAdvisor Limited’s market cap?
MedAdvisor Limited’s market cap is AU$10.84M.
When is MedAdvisor Limited’s upcoming earnings report date?
MedAdvisor Limited’s upcoming earnings report date is Aug 27, 2026 which is in 70 days.
How were MedAdvisor Limited’s earnings last quarter?
MedAdvisor Limited released its earnings results on Feb 26, 2026. The company reported AU$0.011 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.011.
Is MedAdvisor Limited overvalued?
According to Wall Street analysts MedAdvisor Limited’s price is currently Undervalued.
Does MedAdvisor Limited pay dividends?
MedAdvisor Limited does not currently pay dividends.
What is MedAdvisor Limited’s EPS estimate?
MedAdvisor Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MedAdvisor Limited have?
MedAdvisor Limited has 637,676,800 shares outstanding.
What happened to MedAdvisor Limited’s price movement after its last earnings report?
MedAdvisor Limited reported an EPS of AU$0.011 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MedAdvisor Limited?
Currently, no hedge funds are holding shares in AU:AHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MedAdvisor Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AHE Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$20.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.95%
12-Months-Change
Fundamentals
Return on Equity
-209.68%
Trailing 12-Months
Asset Growth
-72.24%
Trailing 12-Months
Company Description
MedAdvisor Limited
Adheris Health Limited, through its affiliates, specializes in delivering pharmacy-led patient interaction platforms. It serves markets in Australia, the United States, and the United Kingdom. The company's flagship product is THRiV, an integrated omni-channel system. THRiV aims to optimize medication adherence and administration by empowering pharmacies to foster engagement with both patients and fellow pharmacists. Formerly operating as MedAdvisor Limited, the company adopted the Adheris Health Limited designation in November 2025. Established in 2010, its corporate base is situated in Woburn, Massachusetts.
Options Prices
Currently, No data available
---